Shield Therapeutics, a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, has appointed Rolf Hoffman as Non-Executive Director following a successful executive search conducted by The RSA Group.
Rolf brings to Shield over 30 years of international pharmaceutical experience having served in several senior roles in the industry, most recently 12 years with Amgen as Senior Vice President of Commercial Operations for the United States, and before that as SVP International and Europe. He started his pharmaceutical career at Eli Lilly as a sales representative, progressing to senior positions including President of Latin America operations and General Manager in Germany. Rolf holds an MBA from the University of North Carolina, a master’s degree from the University of Cologne and is Adjunct Professor at UNC Kenan-Flagler Business School.
Nick Stephens, The RSA Group Executive Chairman, commented: “We’re pleased to have been part of helping Shield Therapeutics in securing the services of Rolf Hoffmann as a Non Executive Director. He will bring knowledge, skills and network to the company that will facilitate its next strategic moves.”
Read the full release here: https://www.shieldtherapeutics.com/wp-content/uploads/2018/04/STX_Confirms-NED-appointment.pdf